Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-014095
Filing Date
2022-05-12
Accepted
2022-05-12 16:25:17
Documents
75
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q xfor-20220331.htm   iXBRL 10-Q 1397589
2 EX-31.1 ex-311q12022.htm EX-31.1 9357
3 EX-31.2 ex-312q12022.htm EX-31.2 9349
4 EX-32.1 ex-321q12022.htm EX-32.1 7058
10 xfor-20220331_g1.jpg GRAPHIC 168920
  Complete submission text file 0001628280-22-014095.txt   6473358

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20220331.xsd EX-101.SCH 51449
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xfor-20220331_cal.xml EX-101.CAL 59554
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xfor-20220331_def.xml EX-101.DEF 166898
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20220331_lab.xml EX-101.LAB 553390
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20220331_pre.xml EX-101.PRE 348143
69 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20220331_htm.xml XML 864860
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38295 | Film No.: 22918219
SIC: 2836 Biological Products, (No Diagnostic Substances)